Home » Drug Information » FDA-Approved Drugs » 1998
Medical Areas: Endocrinology | Immunology/Infectious Diseases | Nephrology/Urology
View By: Year Company Therapeutic Areas Drug Names
Drug Information
The following information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Novartis
Approval Status: Approved May 1998
Treatment Area: acute organ transplant rejection
Simulect has been approved for acute rejection episodes in renal
transplant recipients.
Simulect works by blocking the receptor for IL-2, a protein that
simulates proliferation of T-lymphocytes, which play a key role in
organ transplant rejection.
